BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31958813)

  • 21. Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.
    Segal E; Martens M; Wang HL; Brazauskas R; Weisdorf D; Sandmaier BM; Khoury HJ; de Lima M; Saber W
    Cancer; 2017 Sep; 123(17):3346-3355. PubMed ID: 28452054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic transplantation for patients with advanced acute leukemia: a single center retrospective study of 92 patients.
    Boiron JM; Lerner D; Pigneux A; Fabères C; Bordessoule D; Turlure P; Cony-Makhoul P; Hau F; Dazey B; Agape P; Reiffers J; Marit G
    Leuk Lymphoma; 2001 Apr; 41(3-4):285-96. PubMed ID: 11378541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Donor Genotype in the Interleukin-7 Receptor α-Chain Predicts Risk of Graft-versus-Host Disease and Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.
    Kielsen K; Enevold C; Heilmann C; Sengeløv H; Pedersen AE; Ryder LP; Müller K
    Front Immunol; 2018; 9():109. PubMed ID: 29456530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
    van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A
    Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era.
    Majhail NS; Chitphakdithai P; Logan B; King R; Devine S; Rossmann SN; Hale G; Hartzman RJ; Karanes C; Laport GG; Nemecek E; Snyder EL; Switzer GE; Miller J; Navarro W; Confer DL; Levine JE
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):142-50. PubMed ID: 25445638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants.
    Hill BT; Bolwell BJ; Rybicki L; Dean R; Kalaycio M; Pohlman B; Tench S; Sobecks R; Andresen S; Copelan E
    Biol Blood Marrow Transplant; 2010 Dec; 16(12):1738-46. PubMed ID: 20558313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival Impact of Early Post-Transplant Toxicities in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Nonmalignant Diseases: Recognizing Risks and Optimizing Outcomes.
    Al Mulla N; Kahn JM; Jin Z; Qureshi M; Karamehmet E; Yoon-Jeong Kim G; Levinson AL; Bhatia M; Garvin JH; George D; Kung AL; Satwani P
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1525-1530. PubMed ID: 27223110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study.
    McDonald GB; Evans AT; McCune JS; Schoch G; Ostrow JD; Gooley TA
    Lancet Haematol; 2016 Nov; 3(11):e516-e525. PubMed ID: 27968820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies.
    Konuma T; Kato S; Oiwa-Monna M; Ishii H; Tojo A; Takahashi S
    Leuk Lymphoma; 2016 Sep; 57(9):2126-32. PubMed ID: 26769297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes.
    Dalle JH; Balduzzi A; Bader P; Lankester A; Yaniv I; Wachowiak J; Pieczonka A; Bierings M; Yesilipek A; Sedlaçek P; Ifversen M; Sufliarska S; Toporski J; Glogova E; Poetschger U; Peters C
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1848-1855. PubMed ID: 29772352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis.
    Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Cereb N; Haagenson MD; Spellman SR; Lee SJ; Guethlein LA; Parham P; Miller JS; Cooley SA
    Biol Blood Marrow Transplant; 2019 May; 25(5):949-954. PubMed ID: 30594542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
    Decroocq J; Itzykson R; Vigouroux S; Michallet M; Yakoub-Agha I; Huynh A; Beckerich F; Suarez F; Chevallier P; Nguyen-Quoc S; Ledoux MP; Clement L; Hicheri Y; Guillerm G; Cornillon J; Contentin N; Carre M; Maillard N; Mercier M; Mohty M; Beguin Y; Bourhis JH; Charbonnier A; Dauriac C; Bay JO; Blaise D; Deconinck E; Jubert C; Raus N; Peffault de Latour R; Dhedin N
    Am J Hematol; 2018 Mar; 93(3):416-423. PubMed ID: 29226497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
    Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
    Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
    Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
    Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A
    Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study.
    Ruggeri A; Battipaglia G; Labopin M; Ehninger G; Beelen D; Tischer J; Ganser A; Schwerdtfeger R; Glass B; Finke J; Michallet M; Stelljes M; Jindra P; Arnold R; Kröger N; Mohty M; Nagler A
    J Hematol Oncol; 2016 Sep; 9(1):89. PubMed ID: 27639553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
    Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN; Bachanova V; Bacher U; Dahi P; de Lima M; D'Souza A; Fenske TS; Ganguly S; Kharfan-Dabaja MA; Prestidge TD; Savani BN; Smith SM; Sureda AM; Waller EK; Jaglowski S; Herrera AF; Armand P; Salit RB; Wagner-Johnston ND; Fuchs E; Bolaños-Meade J; Hamadani M
    J Clin Oncol; 2016 Sep; 34(26):3141-9. PubMed ID: 27269951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.